by Site Dev | Oct 26, 2021 | Clinical Trials, Prostate
Prostate Cancer Clinical Trials Contact Us 1) First Line Metastatic mCRPC: USO #19191: BMS CA209-7DX: A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer...
